Asset profile
TDM-180935
Small molecule
Evidence outlook · lead readout
NCT06363461 · Atopic Dermatitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06363461: The study was randomized, double-blinded for participants and outcome assessors, and placebo-controlled, with change in the clinical m-EASI score as its primary endpoint. However, only 24 participants were enrolled and no primary endpoint results are available, so the trial provides limited evidence at this time.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.